Onclive Team

Articles

Reprogramming Pancreatic Cancer

July 11th 2019

New findings may lead to novel immunotherapies against third-deadliest cancer.

A Rare but Treatable Disease: Therapeutic Considerations for Hairy Cell Leukemia

July 11th 2019

Martin S. Tallman, MD, discusses the biology, presentation, and available therapeutic options in hairy cell leukemia.

Hairy Cell Leukemia Pathogenesis, Diagnosis, and Prognosis

July 10th 2019

The pathogenesis, diagnostic criteria, staging, and prognosis of hairy cell leukemia, an uncommon indolent B-cell lymphoid neoplasm, is examined.

Treatment of Hairy Cell Leukemia: Overview and First-Line Options

July 8th 2019

Hairy cell leukemia is a rare malignancy for which treatment has progressed significantly in recent years.

The Shifting Therapeutic Spectrum for Chronic Lymphocytic Leukemia

July 8th 2019

For patients with chronic lymphocytic leukemia, including those with high-risk disease, the availability of novel targeted therapies and monoclonal antibodies offers an increased potential for improved outcomes.

Chronic Lymphocytic Leukemia: Updates in Diagnosis and Testing

July 8th 2019

There have been updates in chronic lymphocytic leukemia prevalence and diagnosis, with an emphasis on testing options.

New Directions in Chronic Lymphocytic Leukemia Care: A Review of 2019 Treatment Guideline Updates

July 8th 2019

In December 2018, pivotal trial data were presented at the ASH Annual Meeting that demonstrated promising results for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia. In particular, new courses of CLL care in several patient populations emerged from the findings of 3 trials.

An Investigator's Perspective on the Chronic Lymphocytic Leukemia Research Front

July 8th 2019

Jennifer Woyach, MD, discusses the current treatment spectrum of chronic lymphocytic leukemia and the significance of the ALLIANCE trial.

Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia

July 8th 2019

Matthew S. Davids, MD, MMSc, characterizes the significance of the ALLIANCE, ECOG E1912, and iLLUMINATE trials within the broader treatment spectrum for chronic lymphocytic leukemia.

Hearing About Breakthroughs Made in Hematologic Malignancies in Boston

June 26th 2019

We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the faculty from Dana-Farber Cancer Institute.

Discussing Pivotal Progress in Breast Cancer in Dallas

June 19th 2019

We traveled to Dallas, Texas, for a State of the Science Summit™ on Breast Cancer, where faculty relayed the prognostic value of genomic assays in breast cancer and the scope of established and ensuing treatment approaches for those with early-stage and advanced disease.

Acalabrutinib Monotherapy Safe, Significantly Improves PFS in Relapsed/Refractory CLL

June 16th 2019

Among the most highly anticipated study results to be presented during the 2019 European Hematology Association Congress were those of the phase III ASCEND trial, which investigated the use of acalabrutinib monotherapy in patients with previously-treated chronic lymphocytic leukemia.

Contemplating Key Updates in GI Cancers in Charlotte

June 12th 2019

We recently traveled to Charlotte, North Carolina, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured expert insight on treatment approaches across metastatic colorectal cancer, locally advanced and metastatic pancreatic cancer, advanced hepatocellular carcinoma, neuroendocrine tumors, and advanced gastric cancer.

Palbociclib Demonstrates Activity in Acral Lentiginous Melanoma Subtype

June 12th 2019

The CDK4/6 inhibitor palbociclib exhibited preliminary activity in patients with acral lentiginous melanoma associated with CDK-pathway aberrations, according to results of a small phase II trial that were reported at the 2019 ASCO Annual Meeting.

Neoadjuvant T-VEC May Reduce Recurrence in Operable Melanoma

June 6th 2019

Neoadjuvant treatment with the oncolytic immunotherapeutic agent talimogene laherparepvec (T-VEC; Imlygic) led to significant improvement in 1-year recurrence-free survival for patients with resectable advanced melanoma compared with surgery alone.

Dabrafenib/Trametinib Combo Provides Lasting Control for BRAF V600-Mutant Metastatic Melanoma

June 6th 2019

Five years out, one-third of patients with unresectable or metastatic BRAF V600-mutant melanoma remained alive following treatment with dual targeted therapy with dabrafenib (Tafinlar) plus trametinib (Mekinist), and 1 in 5 remained alive without progression.

Acalabrutinib Combo Induces High Responses in CLL

June 5th 2019

Simultaneous targeting of Bruton’s tyrosine kinase and the CD20 antigen led to overall responses in more than 90% of patients with chronic lymphocytic leukemia, including untreated and relapsed/refractory disease.

Niraparib/Bevacizumab Combo Active in Recurrent Ovarian Cancer

June 4th 2019

A chemotherapy-free doublet for platinum-sensitive recurrent ovarian cancer more than doubled progression-free survival as compared with single-agent PARP inhibitor.

Atezolizumab Boosts Survival in Patients With NSCLC, Liver Mets

June 3rd 2019

Patients with non–small cell lung cancer and baseline liver metastases had improved progression-free survival and overall survival with the addition of immunotherapy to bevacizumab and a chemotherapy doublet.

Observing the Latest Developments in Ovarian Cancer in NYC

May 29th 2019

We traveled to New York City, New York, for a State of the Science Summit™ on Ovarian Cancer, where faculty shared their insight on the various surgical and medical treatment modalities in advanced ovarian cancer, as well as investigational interventions that may further define standards of care.